Literature DB >> 16377725

Low correlation between MIC and mutant prevention concentration.

Karl Drlica, Xilin Zhao, Joseph M Blondeau, Christine Hesje.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16377725      PMCID： PMC1346827          DOI： 10.1128/AAC.50.1.403-404.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  11 in total

1.  Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.

Authors:  Xinying Li; Xilin Zhao; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae.

Authors:  Glen T Hansen; Kelli Metzler; Karl Drlica; Joseph M Blondeau
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

3.  Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli.

Authors:  Linda L Marcusson; Sara K Olofsson; Patricia Komp Lindgren; Otto Cars; Diarmaid Hughes
Journal:  J Antimicrob Chemother       Date:  2005-04-28       Impact factor: 5.790

4.  Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window.

Authors:  Xilin Zhao; Karl Drlica
Journal:  J Infect Dis       Date:  2002-01-31       Impact factor: 5.226

5.  Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments.

Authors:  Jeffrey J Campion; Patrick J McNamara; Martin E Evans
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

6.  Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria.

Authors:  G Sindelar; X Zhao; A Liew; Y Dong; T Lu; J Zhou; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

7.  Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.

Authors:  Xilin Zhao; William Eisner; Nathan Perl-Rosenthal; Barry Kreiswirth; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

8.  Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions.

Authors:  Hans-Jörg Linde; Norbert Lehn
Journal:  J Antimicrob Chemother       Date:  2003-12-19       Impact factor: 5.790

9.  Mutant prevention concentrations of ciprofloxacin and enrofloxacin for Salmonella enterica.

Authors:  L P Randall; S W Cooles; L J V Piddock; M J Woodward
Journal:  J Antimicrob Chemother       Date:  2004-07-08       Impact factor: 5.790

10.  Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus.

Authors:  K Metzler; G M Hansen; Peter Hedlin; Elizabeth Harding; Karl Drlica; J M Blondeau
Journal:  Int J Antimicrob Agents       Date:  2004-08       Impact factor: 5.283
View more
  10 in total

1.  beta-Lactam MICs correlate poorly with mutant prevention concentrations for clinical isolates of Acinetobacter spp. and Pseudomonas aeruginosa.

Authors:  Juliana Gugel; Andrea Dos Santos Pereira; Antônio C C Pignatari; Ana C Gales
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 2.  A unified anti-mutant dosing strategy.

Authors:  Xilin Zhao; Karl Drlica
Journal:  J Antimicrob Chemother       Date:  2008-06-10       Impact factor: 5.790

3.  Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacin-resistant subpopulations of Staphylococcus aureus.

Authors:  Beibei Liang; Nan Bai; Yun Cai; Rui Wang; Karl Drlica; Xilin Zhao
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

Review 4.  Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.

Authors:  Devan Jaganath; H Simon Schaaf; Peter R Donald
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

5.  Antibacterial activities of nemonoxacin against clinical isolates of Staphylococcus aureus: an in vitro comparison with three fluoroquinolones.

Authors:  Zhaoxia Li; Youning Liu; Rui Wang; Aimin Li
Journal:  World J Microbiol Biotechnol       Date:  2014-08-18       Impact factor: 3.312

6.  Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model.

Authors:  Xin Li; Lin Wang; Xian-Jia Zhang; Yang Yang; Wei-Tao Gong; Bin Xu; Ying-Qun Zhu; Wei Liu
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

7.  Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study.

Authors:  Ai-Jun Pan; Qing Mei; Ying Ye; Hong-Ru Li; Bao Liu; Jia-Bin Li
Journal:  J Antibiot (Tokyo)       Date:  2016-10-19       Impact factor: 2.649

Review 8.  Quinolones: action and resistance updated.

Authors:  Karl Drlica; Hiroshi Hiasa; Robert Kerns; Muhammad Malik; Arkady Mustaev; Xilin Zhao
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

9.  Synergistic combination of two antimicrobial agents closing each other's mutant selection windows to prevent antimicrobial resistance.

Authors:  Xuejie Xu; Li Xu; Ganjun Yuan; Yimin Wang; Yunqiu Qu; Meijing Zhou
Journal:  Sci Rep       Date:  2018-05-08       Impact factor: 4.379

10.  Evolution of antibiotic cross-resistance and collateral sensitivity in Staphylococcus epidermidis using the mutant prevention concentration and the mutant selection window.

Authors:  Natalie Ann Lozano-Huntelman; Nina Singh; Alondra Valencia; Portia Mira; Maral Sakayan; Ian Boucher; Sharon Tang; Kelley Brennan; Crystal Gianvecchio; Sorel Fitz-Gibbon; Pamela Yeh
Journal:  Evol Appl       Date:  2020-02-25       Impact factor: 5.183
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.